Business
TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders
BERLIN, May 26, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 03.00 p.m. CEST on June 25, 2025, at the offices of Freshfields LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/95b0af6c7c345eddc194593c304d1274"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xzpmKFi__4VKo5KUpYso5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/95b0af6c7c345eddc194593c304d1274","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BoRKf9zZx5YzI9FqXE3kYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/95b0af6c7c345eddc194593c304d1274","width":1000,"height":313}},"lazy":false},{"type":"text","content":"BERLIN, May 26, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 03.00 p.m. CEST on June 25, 2025, at the offices of Freshfields LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.","length":426,"tagName":"p"},{"type":"text","content":"Following the announcement on May 05, 2025, one item on the agenda at the AGM will be voting on the appointment of Diede Mink van den Ouden as Chief Executive Officer of TME Pharma N.V. through the binding nomination of the Supervisory Board. Mr. van den Ouden (44) has been a professional investor since 2008 with a proven track record as investor in listed company for many years. His knowledge and experience enable him to manage the constantly changing market conditions well.","length":480,"tagName":"p"},{"type":"text","content":"Currently, and since September 2024 Mr. van den Ouden serves as CEO and President of Tonner Drones SA, listed on Euronext Growth Paris. From December 2022 to January 2025, he was CEO of Lavide Holding NV where he successfully led a reorganization and ensured a good future for this company by finding the right partner in Haerlem Capital. As an investor, he regularly played an advisory role to the management of other listed companies.","length":436,"tagName":"p"},{"type":"text","content":"At the...